Search
To identify links between drug resistance and gene deregulation we used oligonucleotide microarray technology.
We report a term male with congenital acute erythroleukemia who achieved sustained remission with low-dose cytosine arabinoside alone
Present a valuable resource for drug discovery and have identified ROM as a promising therapeutic for MLL-rearranged iALL
In recent decades, the conduct of uniform prospective clinical trials has led to improved remission rates and survival for patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. However, high-risk patients continue to have inferior outcomes, where chemoresistance and relapse are common due to the survival mechanisms utilised by leukaemic cells.
Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.
Early intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant acute lymphoblastic leukemia
Drug-resistant forms of acute lymphoblastic leukaemia (ALL) are a leading cause of death from disease in children.
This study describes the development and molecular characterization of a panel of patient-derived infant leukemia oncogene xenografts and their sensitivity...
Investigation of this rare mixed lineage leukemia cytogenetic abnormality aims to provide further evidence of the genetic changes that underpin this leukemia.
We hypothesized that reactivation of p53 by inhibition of its negative regulator will result in p53-mediated growth arrest and apoptosis.